1-(1H-Indazol-3-yl)-N-methylmethanamine | 1820943-86-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(1H-Indazol-3-yl)-N-methylmethanamine
• 英文别名: 1-(2H-indazol-3-yl)-N-methylmethanamine
• CAS: 1820943-86-9
• 化学式: C₉H₁₁N₃
• 分子量: 161.2
• InChiKey: KYAJOMMSWZGJJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• PYRIMIDINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20130310373A1

  公开（公告）日：2013-11-21

  [Problems] Provided is a novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. [Means for Solution] It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like, thereby the present invention was completed.

  【问题】提供了一种基于对大麻素类2受体的激动作用，用于预防和/或治疗与大麻素类2受体相关的疾病的新颖和优秀的方法。 【解决方案手段】发现一种异杂环衍生物，其主要具有两个取代基，例如，在2位具有取代的嘧啶-5-羧酰胺衍生物表现出对大麻素类2受体的强效激动作用，可作为预防和/或治疗与大麻素类2受体相关的疾病的药物，例如炎症性疾病、疼痛等，因此完成了本发明。
• TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160152628A1

  公开（公告）日：2016-06-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗心血管，平滑肌，肿瘤，神经病理，自身免疫，纤维化和/或炎症性疾病的方法。
• NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP3135668A1

  公开（公告）日：2017-03-01

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型二取代1,2,4-三嗪化合物或其药学上可接受的盐，该化合物具有醛固酮合成酶抑制活性，可用于预防和/或治疗与醛固酮相关的各种疾病或病症；本发明还提供了一种制备方法；本发明的用途；以及一种以本发明为活性成分的药物组合物。通式[I]的化合物： 其中RA例如为下式(A-1)的基团： 其中环 A1 例如是可被取代的环烷基、 RB例如为单环环烷基、 或其药学上可接受的盐。
• Disubstituted 1, 2, 4-triazine compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10029993B2

  公开（公告）日：2018-07-24

  This invention provides a novel disubstituted 1,2,4-triazine compound or a pharmaceutically acceptable salt thereof, which has an aldosterone synthetase inhibitory activity and is useful for preventing and/or treating various diseases or conditions associated with aldosterone; a method for preparing it; use of it; as well as a pharmaceutical composition comprising it as an active ingredient. A compound of the general formula [I]: wherein RA is, for example, a group of the following formula (A-1): wherein ring A1 is, for example, a cycloalkyl group which may be substituted, and RB is, for example, a monocyclic cycloalkyl group, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种新型二取代1,2,4-三嗪化合物或其药学上可接受的盐，该化合物具有醛固酮合成酶抑制活性，可用于预防和/或治疗与醛固酮相关的各种疾病或病症；本发明还提供了一种制备方法；本发明的用途；以及一种以本发明为活性成分的药物组合物。通式[I]的化合物： 其中 RA 是例如下式（A-1）的基团： 其中，环 A1 例如是可被取代的环烷基，RB 例如是单环环烷基、 或其药学上可接受的盐。
• NEW COMPOUNDS
  申请人：Engelhardt Harald

  公开号：US20100222331A1

  公开（公告）日：2010-09-02

  The present invention encompasses compounds of general Formula (1) wherein R 2 , R 3 , Q, W, X, Y and Z are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.